title: Minimal change nephrotic syndrome associated with gefitinib and a successful switch to erlotinib.
abstract: Minimal change nephrotic syndrome (MCNS) is a common form of nephrotic syndrome (NS). We herein present the case of a 57-year-old woman with advanced lung adenocarcinoma treated with the tyrosine kinase inhibitor (TKI) gefitinib who developed NS. A renal biopsy revealed minor glomerular abnormalities, and the patient's symptoms improved exclusively with the discontinuation of gefitinib. Therefore, we diagnosed her with MCNS associated with gefitinib treatment. A few months later, however, she developed recurrent lung tumors. Following the challenging initiation of the TKI erlotinib, she achieved remission without proteinuria. We thus conclude that erlotinib is a potential treatment option in patients with NS associated with gefitinib therapy.
authors.affiliation: Division of Cardiology, Nephrology, Pulmonology and Neurology, Department of Internal Medicine, Asahikawa Medical University, Japan.
authors.forename: Keisuke
authors.initials: K
authors.lastname: Maruyama
authors.forename: Junko
authors.initials: J
authors.lastname: Chinda
authors.forename: Tatsuki
authors.initials: T
authors.lastname: Kuroshima
authors.forename: Maki
authors.initials: M
authors.lastname: Kabara
authors.forename: Naoki
authors.initials: N
authors.lastname: Nakagawa
authors.forename: Takayuki
authors.initials: T
authors.lastname: Fujino
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Ohsaki
authors.forename: Yayoi
authors.initials: Y
authors.lastname: Ogawa
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Hasebe
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D000077192:Adenocarcinoma of Lung; D000970:Antineoplastic Agents / Q000009:adverse effects*; D057915:Drug Substitution; D000069347:Erlotinib Hydrochloride; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D009402:Nephrosis, Lipoid / Q000139:chemically induced* / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib